Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-04, Stock:NVS, The news for the past five days is as follows:
2018-03-27: NEWS1: What Happened in the Stock Market Today.NEWS2: What Happened in the Stock Market Today.NEWS3: What Happened in the Stock Market Today.NEWS4: Health Care Sector Update for 03/27/2018: BMY,ANAB,NVS,GSK,MGEN.NEWS5: Health Care Sector Update for 03/27/2018: BMY,ANAB,NVS,GSK,MGEN.NEWS6: GlaxoSmithKline Buys Novartis Share Of Health Unit For $13 Billion.NEWS7: GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal.NEWS8: GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal.NEWS9: The Dow Plunges Into the Close of Trading on Tuesday.NEWS10: Health Care Sector Update for 03/27/2018: ANAB,NVS,GSK,MGEN.NEWS11: Health Care Sector Update for 03/27/2018: ANAB,NVS,GSK,MGEN.NEWS12: Novartis's New CEO Has Cash and Momentum for an Overhaul.NEWS13: GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal.NEWS14: GlaxoSmithKline up on buy, Red Hat shares climbing on earnings, Overstock down on offering.GlaxoSmithKline, Red Hat and Overstock are today's charts.NEWS15: GlaxoSmithKline To Buy Novartis' Stake in Consumer Health Care JV For $13 Billion.NEWS16: Wall Street Sees Upbeat Session on Cooling Trade Tensions.NEWS17: Wall Street Sees Upbeat Session on Cooling Trade Tensions.NEWS18: Health Care Sector Update for 03/27/2018: MGEN, BMY, TSRO, ZOM, NVS, GSK.NEWS19: Health Care Sector Update for 03/27/2018: MGEN, BMY, TSRO, ZOM, NVS, GSK.NEWS20: GSK buys out Novartis in $13 billion consumer healthcare shake-up.NEWS21: Stock futures in the green, US-China trade talks calm investors.NEWS22: US Futures Gain on Cooling Trade Tensions.NEWS23: US Futures Gain on Cooling Trade Tensions.NEWS24: [$$] GSK Buys Novartis's Stake in Health-Care Unit for $13 Billion.NEWS25: Investor Expectations to Drive Momentum within Ambev S.A, AC Immune SA, Comp En De Mn Cemig ADS, GSV Capital, Novartis AG, and New York — Discovering Underlying Factors of Influence.NEWS26: [$$] Walmsley still has a lot to do to bring GSK back to health.NEWS27: European Markets Rebounded As Trade War Concerns Ease.NEWS28: European Markets Rebounded As Trade War Concerns Ease.NEWS29: The Swiss Stock Market Climbed As Trade Tensions Improve.NEWS30: The Swiss Stock Market Climbed As Trade Tensions Improve.NEWS31: GSK's $13 Billion Novartis Deal Is Only Just the Start.NEWS32: Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday.NEWS33: Facebook, Novartis, GSK, Uber and Deutsche Bank - 5 Things You Must Know.NEWS34: GSK buys out Novartis in $13bln shake-up.NEWS35: GSK Shares Surge on $13B Buyout Deal Struck With Novartis.NEWS36: [$$] Stocks to watch: GSK, Ferguson, Superdry, H&M, Zurich Insurance.NEWS37: GSK buys out Novartis in $13 billion consumer healthcare shake-up.NEWS38: GlaxoSmithKline Is Buying Out Novartis’s Share in Their Consumer Health Joint Venture.NEWS39: [$$] Novartis sells stake in consumer business to GSK for $13bn.NEWS40: GSK To Buyout Novartis' Stake In Consumer Healthcare JV For $13 Bln; Stock Up.NEWS41: GSK To Buyout Novartis' Stake In Consumer Healthcare JV For $13 Bln; Stock Up.NEWS42: Novartis sells joint venture stake to GSK for $13 billion.NEWS43: European Shares Follow Wall Street Higher As Trade Worries Ease.NEWS44: European Shares Follow Wall Street Higher As Trade Worries Ease.NEWS45: [$$] GSK to Buy Novartis Stake in Consumer Health JV.NEWS46: FTSE 100 Surges Amid Global Rally.NEWS47: FTSE 100 Surges Amid Global Rally.NEWS48: [$$] Novartis sells stake in joint venture to GSK for $13bn.NEWS49: GSK buys Novartis stake in consumer healthcare venture for $13 billion.NEWS50: Novartis selling consumer-healthcare JV stake to GlaxoSmithKline.NEWS51: GSK Gets Full Control of Sensodyne Maker for $13 Billion.NEWS52: Glaxo to Buy Novartis Consumer-Venture Stake for $13 Billion.NEWS53: Novartis CEO on Alcon and Sandoz.NEWS54: Novartis CEO: Any potential decision on eye-care business will be made in first half of 2019.NEWS55: CNBC Transcript: Vasant Narasimhan, CEO, Novartis.NEWS56: GSK To Acquire Novartis' Stake In Consumer Healthcare JV For $13.0 Bln.NEWS57: GSK To Acquire Novartis' Stake In Consumer Healthcare JV For $13.0 Bln.
2018-03-28: NEWS1: How Did Novartis’s Gleevec, Tasigna, and Sandostatin Perform in 4Q17?.NEWS2: How Did Novartis’s Gleevec, Tasigna, and Sandostatin Perform in 4Q17?.NEWS3: How Novartis’s Oncology Segment Drugs Are Performing.NEWS4: How Did Novartis Perform in 4Q17 and Full-Year 2017?.NEWS5: Company News For Mar 28, 2018.NEWS6: Company News For Mar 28, 2018.NEWS7: European ADRs Move Higher in Wednesday Trading.NEWS8: European ADRs Move Higher in Wednesday Trading.NEWS9: Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV.NEWS10: Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV.NEWS11: Company News For Mar 28, 2018.NEWS12: Health care trumps terrorism, gun violence concerns for Americans.NEWS13: In Battle To Cut Drug Prices, Outcome-Based Pricing Carries Big Risks For Biopharma.NEWS14: Glaxo (GSK) Buys Novartis&apos; Stake in Consumer Healthcare JV.NEWS15: The Swiss Stock Market Jumped On Strength Of Defensive Heavyweights.NEWS16: The Swiss Stock Market Jumped On Strength Of Defensive Heavyweights.NEWS17: Novartis AG -- Moody's: Novartis's sale of joint venture stake could be credit positive, but uncertainty around use of proceeds and financial policies persist.NEWS18: Biotech Stocks Facing FDA Decision In April.NEWS19: Biotech Stocks Facing FDA Decision In April.NEWS20: [$$] GSK Buys Novartis’s Stake in Health-Care Unit for $13 Billion.NEWS21: [$$] Inside story about the past few weeks of dealmaking at GSK.
2018-03-29: NEWS1: Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster.NEWS2: Novartis Likely Delayed In Launching Copycat Of Amgen Blockbuster.NEWS3: What’s Merck’s Valuation in March 2018?.NEWS4: What’s Merck’s Valuation in March 2018?.NEWS5: Exclusive: Penn patient shares the story of her CAR-T cell therapy journey.NEWS6: Exclusive: Penn patient shares the story of her CAR-T cell therapy journey.NEWS7: How Is Novartis’s Cosentyx Positioned after 4Q17?.NEWS8: How Novartis’s Ophthalmology Business Performed in 2017.NEWS9: How Novartis’s Ophthalmology Business Performed in 2017.NEWS10: The Swiss Stock Market Fell On Pharma Weakness.NEWS11: The Swiss Stock Market Fell On Pharma Weakness.NEWS12: How Merck Stock Has Performed Recently.NEWS13: How Merck Stock Has Performed Recently.NEWS14: How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?.NEWS15: How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?.
2018-04-02: NEWS1: Puma's Shares Fall This Year Post a Solid 2017: Here's Why.NEWS2: Puma's Shares Fall This Year Post a Solid 2017: Here's Why.NEWS3: On World Autism Awareness Day, A Look At Biotech Firms With Potential Treatments In The Pipeline.NEWS4: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS5: Shire's Stock Continues to Rise as Takeda Sets Eyes On it.NEWS6: VEA, EFU: Big ETF Inflows.NEWS7: VEA, EFU: Big ETF Inflows.NEWS8: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS9: How Novartis’s Alcon Performed in 4Q17 and Fiscal 2017.NEWS10: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS11: How Did Sandoz Perform in 4Q17 and Fiscal 2017?.NEWS12: How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed.NEWS13: How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed.NEWS14: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.NEWS15: Analysts’ Recommendations for Bristol-Myers Squibb in March 2018.
2018-04-03: NEWS1: CASI Makes Case For Hope, MYND On Track, URGN Sprints, No Stopping INNT.NEWS2: CASI Makes Case For Hope, MYND On Track, URGN Sprints, No Stopping INNT.NEWS3: Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs.NEWS4: Pfizer Takes On Gilead, Novartis With New Deal In Cancer Drugs.NEWS5: Why GlaxoSmithKline Stock Rose in the Week Ended March 29.NEWS6: Why GlaxoSmithKline Stock Rose in the Week Ended March 29.NEWS7: Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label.NEWS8: Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label.NEWS9: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS10: Better Buy: Acadia Pharmaceuticals vs. Eli Lilly.NEWS11: The Swiss Stock Market Begins The Week With A Substantial Loss.NEWS12: The Swiss Stock Market Begins The Week With A Substantial Loss.NEWS13: What Analysts Recommend for Novartis in March 2018.NEWS14: What Analysts Recommend for Novartis in March 2018.NEWS15: Will These Drugs Reach Blockbuster Status?.NEWS16: Will These Drugs Reach Blockbuster Status?.

Answer: Rise